Fox Run Management L.L.C. Takes $216,000 Position in Health Catalyst, Inc. (NASDAQ:HCAT)

Fox Run Management L.L.C. acquired a new position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 30,576 shares of the company’s stock, valued at approximately $216,000. Fox Run Management L.L.C. owned about 0.05% of Health Catalyst at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of HCAT. Fred Alger Management LLC purchased a new stake in shares of Health Catalyst in the 3rd quarter valued at approximately $6,858,000. Portolan Capital Management LLC acquired a new position in shares of Health Catalyst in the 3rd quarter valued at $5,402,000. Palogic Value Management L.P. purchased a new position in shares of Health Catalyst during the 4th quarter worth $2,262,000. Raymond James Financial Inc. acquired a new stake in shares of Health Catalyst during the 4th quarter worth about $2,044,000. Finally, Martin & Co. Inc. TN raised its holdings in Health Catalyst by 80.0% in the 4th quarter. Martin & Co. Inc. TN now owns 490,998 shares of the company’s stock valued at $3,471,000 after buying an additional 218,293 shares during the period. 85.00% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Piper Sandler dropped their target price on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 11th. Royal Bank of Canada cut their price objective on Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating on the stock in a report on Thursday, February 27th. Citigroup lowered their target price on Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a report on Friday, January 10th. Stephens lowered their target price on Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating for the company in a research note on Thursday, March 6th. Finally, Stifel Nicolaus dropped their price target on shares of Health Catalyst from $10.00 to $5.00 and set a “hold” rating on the stock in a research note on Thursday, February 27th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Health Catalyst currently has an average rating of “Moderate Buy” and a consensus price target of $9.27.

Insider Buying and Selling at Health Catalyst

In other news, COO Daniel Lesueur sold 16,902 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total value of $76,397.04. Following the transaction, the chief operating officer now owns 216,250 shares of the company’s stock, valued at approximately $977,450. The trade was a 7.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Benjamin Landry sold 13,827 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $4.55, for a total value of $62,912.85. Following the sale, the general counsel now owns 160,437 shares of the company’s stock, valued at $729,988.35. This trade represents a 7.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 61,030 shares of company stock valued at $330,757 in the last ninety days. Insiders own 2.50% of the company’s stock.

Health Catalyst Stock Down 1.1 %

HCAT stock opened at $4.55 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. Health Catalyst, Inc. has a 12 month low of $3.76 and a 12 month high of $9.24. The company has a fifty day moving average price of $5.03 and a 200 day moving average price of $6.87. The company has a market cap of $319.46 million, a price-to-earnings ratio of -3.37 and a beta of 1.41.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.